SLS Stock Summary and Trading Ideas (Sellas Life Sciences Group | NASDAQ:SLS)

SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.

Sellas Life Sciences Group trades on the NASDAQ stock market under the symbol SLS.

As of December 15, 2025, SLS stock price declined to $1.99 with 1,628,343 million shares trading.

SLS has a beta of 0.99, meaning it tends to be less sensitive to market movements. SLS has a correlation of 0.04 to the broad based SPY ETF.

SLS has a market cap of $283.46 million. This is considered a Small Cap stock.

In the last 3 years, SLS traded as high as $4.13 and as low as $.50.

The top ETF exchange traded funds that SLS belongs to (by Net Assets): VTI, IWM, VXF, IWO, VFMO.

SLS has outperformed the market in the last year with a price return of +131.2% while the SPY ETF gained +14.0%. SLS has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +7.6% and +22.8%, respectively, while the SPY returned +3.9% and -0.3%, respectively.

SLS support price is $1.89 and resistance is $2.17 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SLS shares will trade within this expected range on the day.